Targeting the neurological comorbidities of multiple sclerosis: the beneficial effects of VIP and PACAP neuropeptides.

Jansen, MI; Broome, ST; Castorina, A

Targeting the neurological comorbidities of multiple sclerosis: the beneficial effects of VIP and PACAP neuropeptides.

Jansen, MI Broome, ST Castorina, A

Permalink

Publisher:: IMR Press
Publication Type:: Journal Article
Citation:: J Integr Neurosci, 2022, 21, (1), pp. 33
Issue Date:: 2022-01-28

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (845.39 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Jansen, MI
dc.contributor.author	Broome, ST
dc.contributor.author	Castorina, A https://orcid.org/0000-0001-7037-759X
dc.date.accessioned	2022-03-08T06:14:00Z
dc.date.available	2021-09-13
dc.date.available	2022-03-08T06:14:00Z
dc.date.issued	2022-01-28
dc.identifier.citation	J Integr Neurosci, 2022, 21, (1), pp. 33
dc.identifier.issn	0219-6352
dc.identifier.uri	http://hdl.handle.net/10453/155072
dc.description.abstract	Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are two widely expressed neuropeptides with important immunomodulatory and neuroprotective properties in the central nervous system (CNS). Both VIP and PACAP have been implicated in several neurological diseases and have shown favourable effects in different animal models of multiple sclerosis (MS). MS is a chronic inflammatory and neurodegenerative disease of the CNS affecting over 2.5 million people worldwide. The disease is characterised by extensive neuroinflammation, demyelination and axonal loss. Currently, there is no cure for MS, with treatment options only displaying partial efficacy. Importantly, epidemiological studies in the MS population have demonstrated that there is a high incidence of neurological and psychological comorbidities such as depression, anxiety, epilepsy and stroke among afflicted people. Hence, given the widespread protective effects of the VIP/PACAP system in the CNS, this review will aim at exploring the beneficial roles of VIP and PACAP in ameliorating some of the most common neurological comorbidities associated with MS. The final scope of the review is to put more emphasis on how targeting the VIP/PACAP system may be an effective therapeutic strategy to modify MS disease course and its associated comorbidities.
dc.format	Print
dc.language	eng
dc.publisher	IMR Press
dc.relation	The Rebecca L Cooper Medical Research Foundation L
dc.relation.ispartof	J Integr Neurosci
dc.relation.isbasedon	10.31083/j.jin2101033
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	09 Engineering, 11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	Neurology & Neurosurgery
dc.title	Targeting the neurological comorbidities of multiple sclerosis: the beneficial effects of VIP and PACAP neuropeptides.
dc.type	Journal Article
utslib.citation.volume	21
utslib.location.activity	Singapore
utslib.for	09 Engineering
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2022-03-08T06:13:58Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	21
utslib.citation.issue	1

Abstract:

Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are two widely expressed neuropeptides with important immunomodulatory and neuroprotective properties in the central nervous system (CNS). Both VIP and PACAP have been implicated in several neurological diseases and have shown favourable effects in different animal models of multiple sclerosis (MS). MS is a chronic inflammatory and neurodegenerative disease of the CNS affecting over 2.5 million people worldwide. The disease is characterised by extensive neuroinflammation, demyelination and axonal loss. Currently, there is no cure for MS, with treatment options only displaying partial efficacy. Importantly, epidemiological studies in the MS population have demonstrated that there is a high incidence of neurological and psychological comorbidities such as depression, anxiety, epilepsy and stroke among afflicted people. Hence, given the widespread protective effects of the VIP/PACAP system in the CNS, this review will aim at exploring the beneficial roles of VIP and PACAP in ameliorating some of the most common neurological comorbidities associated with MS. The final scope of the review is to put more emphasis on how targeting the VIP/PACAP system may be an effective therapeutic strategy to modify MS disease course and its associated comorbidities.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/155072